UBS AM’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-179,953
| Closed | -$7.24M | – | 3728 |
|
|
2026
Q1 | $7.24M | Buy |
179,953
+1,065
| +0.6% | +$22.9K | ﹤0.01% | 1381 |
|
|
2025
Q4 | $4.49M | Buy |
178,888
+11,424
| +7% | +$268K | ﹤0.01% | 1513 |
|
|
2025
Q3 | $3.79M | Sell |
167,464
-134,475
| -45% | -$3.14M | ﹤0.01% | 1497 |
|
|
2025
Q2 | $5.23M | Buy |
301,939
+79,305
| +36% | +$1.47M | ﹤0.01% | 1685 |
|
|
2025
Q1 | $4.87M | Buy |
222,634
+9,747
| +5% | +$269K | ﹤0.01% | 1595 |
|
|
2024
Q4 | $6.79M | Buy |
212,887
+21,822
| +11% | +$656K | ﹤0.01% | 1452 |
|
|
2024
Q3 | $5.51M | Sell |
191,065
-17,119
| -8% | -$634K | ﹤0.01% | 1517 |
|
|
2024
Q2 | $7.99M | Buy |
208,184
+68,859
| +49% | +$3.12M | ﹤0.01% | 1230 |
|
|
2024
Q1 | $8.19M | Sell |
139,325
-2,443
| -2% | -$156K | ﹤0.01% | 1069 |
|
|
2023
Q4 | $8.49M | Sell |
141,768
-4,178
| -3% | -$212K | ﹤0.01% | 1053 |
|
|
2023
Q3 | $5.55M | Buy |
145,946
+46,142
| +46% | +$2.03M | ﹤0.01% | 1169 |
|
|
2023
Q2 | $6.58M | Hold |
99,804
| – | – | ﹤0.01% | 1117 |
|
|
2023
Q1 | $6.58M | Buy |
99,804
+24,718
| +33% | +$1.43M | ﹤0.01% | 1117 |
|
|
2022
Q4 | $3.88M | Buy |
75,086
+5,928
| +9% | +$314K | ﹤0.01% | 1253 |
|
|
2022
Q3 | $4.72M | Sell |
69,158
-282,466
| -80% | -$16.7M | ﹤0.01% | 1219 |
|
|
2022
Q2 | $15.9M | Sell |
351,624
-38,516
| -10% | -$1.76M | 0.01% | 794 |
|
|
2022
Q1 | $19.8M | Buy |
390,140
+16,466
| +4% | +$727K | 0.01% | 847 |
|
|
2021
Q4 | $17.7M | Buy |
373,674
+169,684
| +83% | +$6.68M | 0.01% | 933 |
|
|
2021
Q3 | $6.72M | Sell |
203,990
-8,525
| -4% | -$479K | ﹤0.01% | 1241 |
|
|
2021
Q2 | $13.4M | Buy |
212,515
+156,256
| +278% | +$8.06M | 0.01% | 1011 |
|
|
2021
Q1 | $2.41M | Sell |
56,259
-8,688
| -13% | -$411K | ﹤0.01% | 1679 |
|
|
2020
Q4 | $3.71M | Sell |
64,947
-1,908
| -3% | -$80.7K | ﹤0.01% | 1415 |
|
|
2020
Q3 | $2.02M | Buy |
66,855
+1,431
| +2% | +$42.8K | ﹤0.01% | 1541 |
|
|
2020
Q2 | $2.14M | Buy |
65,424
+18,383
| +39% | +$590K | ﹤0.01% | 1495 |
|
|
2020
Q1 | $1.26M | Buy |
47,041
+10,690
| +29% | +$380K | ﹤0.01% | 1604 |
|
|
2019
Q4 | $1.11M | Buy |
36,351
+4,133
| +13% | +$114K | ﹤0.01% | 1861 |
|
|
2019
Q3 | $776K | Buy |
32,218
+18,292
| +131% | +$503K | ﹤0.01% | 2075 |
|
|
2019
Q2 | $353K | Buy |
+13,926
| New | +$283K | ﹤0.01% | 2351 |
|
Other funds holding APLS
UBS AM's APLS Position: Q2 2026 in Review
UBS AM sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 179,953 shares — an estimated $7.24M sold.
UBS AM first reported a position in APLS in Q2 2019 and held it in 28 quarters. The position peaked at $19.8M in Q1 2022. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- UBS AM reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- UBS AM sold 179,953 Apellis Pharmaceuticals shares in Q2 2026, an estimated $7.24M.
- UBS AM first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 28 quarters.
- UBS AM's Apellis Pharmaceuticals position peaked at $19.8M in Q1 2022.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.